Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1:15:241-255.
doi: 10.2147/JPR.S341378. eCollection 2022.

Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch

Denis Dupoiron  1 , Sabrina Jubier-Hamon  1 , Valerie Seegers  2 , Florent Bienfait  1 , Yves Marie Pluchon  3 , Nathalie Lebrec  1 , Virginie Jaoul  1 , Thierry Delorme  1
Affiliations

Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch

Denis Dupoiron et al. J Pain Res. .

Abstract

Purpose: Data supporting the use of high-concentration capsaicin patches (HCCPs) in breast cancer (BC) patients and BC survivors (BCSs) with peripheral neuropathic pain (PNP) are limited. This observational study evaluated the effectiveness and safety of HCCP applications in BCSs/BC patients with PNP.

Patients and methods: Data from all patients treated with HCCP in the pain department of a French comprehensive cancer centre were collected from 01-Jan-2014 to 14-Oct-2020. Independent pain specialists completed the Clinical Global Impression of Change (CGIC) for each included patient based on data extracted from patient's electronic medical record compiled by the treating pain specialist after each HCCP application.

Results: Patients (N=279; mean age: 59.2 years; previous history of PNP medication: 54.5%) received on average 4.1 repeated HCCP applications (1141 HCCP applications); 68.8% received HCCP as an add-on to systemic therapy and 27.9% as first-line therapy. PNP was most frequently caused by surgery (62.4%) followed by chemotherapy (11.8%) and radiotherapy (6.5%). A complete or important analgesic effect was reported at least once by 82.3% of patients. A 6.0% reported no effect at all. For post-surgical PNP existing for <12 months and >10 years an important or complete effect was observed for 70.7% and 56.0% of applications. For chemotherapy- or radiotherapy-induced PNP, this important or complete effect was observed for 52.7% and 52.3% of applications, respectively. HCCP application was associated with site reactions in 54.4% of patients (mainly burning sensation or pain, 45.9%, or erythema, 30.8%) and high blood pressure in 7.2%.

Conclusion: This real-world chart review provides important effectiveness and safety information to clinicians when considering topical options to treat PNP in BCSs/BC patients.

Keywords: breast cancer; capsaicin; chronic pain; effectiveness; peripheral neuropathic pain; safety; topical administration.

PubMed Disclaimer

Conflict of interest statement

D. Dupoiron, S. Jubier-Hamon, Y. M. Pluchon and T. Delorme received consultant fees from Grünenthal. Dr Nathalie Lebrec reports grants from Institut de Cancérologie de L’Ouest -Angers, during the conduct of the study. The authors declare no other conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Description of HCCP applications by location.
Figure 3
Figure 3
Effect of HCCP application on CGIC score. (A) By PNP aetiology. (B) By PNP duration.
Figure 4
Figure 4
Effect of HCCP application on CGIC scores by treatment line.
Figure 5
Figure 5
CGIC scores by patient, pain duration and from first application.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–e1037. doi:10.1016/S2214-109X(20)30215-1 - DOI - PubMed
    1. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090 e9. doi:10.1016/j.jpainsymman.2015.12.340 - DOI - PubMed
    1. Cancer INd. La vie cinq ans après un diagnostic de Cancer – Rapport; 2018.
    1. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985–1992. doi:10.1001/jama.2009.1568 - DOI - PubMed